INTRODUCTION
RAS genes are the key intracellular mediators that transmit signals from cell surface receptors to downstream effector pathways, regulating cell proliferation, survival, and differentiation (Bos, 1989; Downward, 2003) . One of the major RAS-regulated downstream effector pathways is mediated by the extracellular signal-regulated kinase (ERK) subfamily of mitogen-activated protein kinases (MAPKs), which is comprised of a kinase cascade of RAF, MEK, and ERK (Rubinfeld and Seger, 2005) . Somatic-activating mutations in RAS and RAF are among the most frequent gain-of-function alterations in human cancer, highlighting a critical role for the RAS-RAF-MEK-ERK pathway in human oncogenesis (Bos, 1989; Downward, 2003) . Recent studies have revealed that germline mutations in the components of the RAS/ERK pathway are associated with a group of clinically related developmental disorders, including Noonan, LEOPARD, cardio-facio-cutaneous (CFC), Costello, Legius, and neurofibromatosis type 1 (NF1) syndromes, which has been collectively referred to as neuro-cardio-facial-cutaneous (NCFC) syndromes or ''RASopathies'' (Bentires-Alj et al., 2006; Samuels et al., 2009; Schubbert et al., 2007; Tidyman and Rauen, 2009) . One of the most important unknown aspects of NCFC syndromes is the mechanism(s) underlying the substantial neurocognitive burden of these diseases. Particularly, the developmental basis of brain abnormalities in NCFC syndrome patients remains largely unknown.
Most NCFC syndromes are caused by dominant-activating mutations in the RAS/ERK signaling pathway in the germline. However, NF1 is arguably an exception because it is caused by germline recessive loss-of-function mutations in one of the two NF1 alleles (NF1 +/À ) (Bentires-Alj et al., 2006; Samuels et al., 2009; Schubbert et al., 2007; Tidyman and Rauen, 2009 ). The NF1 gene encodes a RAS GTPase-activating protein (GAP) neurofibromin, which promotes the conversion of an active RAS-GTP bound form to an inactive RAS-GDP form, thus functioning as a negative regulator of RAS/ERK signaling pathway (Cichowski and Jacks, 2001) . Between 30% and 70% of NF1 patients have learning disabilities-the most significant cause of lifetime morbidity associated with these patients (Hyman et al., 2005) . Recent studies using genetically engineered mouse (GEM) models have shown that heterozygous Nf1 inactivation (Nf1 +/À ) causes behavioral abnormalities with similarities to learning disabilities in NF1 patients (Cui et al., 2008) . However, Nf1 +/À mice exhibit no evidence of structural brain defects such as enlarged corpus callosum (CC), which has been recently associated with severe learning disabilities observed in a subpopulation of NF1 patients (Moore et al., 2000; Pride et al., 2010) . The CC is comprised of neuronal fibers that connect the two brain hemispheres, as well as the two primary glial cell types: oligodendrocytes that form myelin of axons, and astrocytes that provide trophic and functional support for neurons (Rowitch and Kriegstein, 2010) . The clinical observations that only a subpopulation of NF1 patients exhibits an enlarged CC argue that monoallelic NF1 inactivation (NF1 +/À ) is not sufficient to induce these structural brain defects. It has recently been shown that some NF1-related nontumor manifestations such as skin hyperpigmentation and bone abnormalities result from biallelic NF1 inactivation (NF1 À/À ) caused by ''second-hit'' mutations in the remaining wild-type NF1 alleles of somatic cells (De Schepper et al., 2008; Stevenson et al., 2006) . Accordingly, we hypothesize that the structural brain defects such as the enlarged CC observed in a subset of NF1 patients could be caused by biallelic NF1 inactivation in developing neural stem cells. Compared to differentiated cells, stem cells have greater potentials for self-renewal, and consequently, one or few NF1 À/À stem cells could produce a greater number of progeny that manifest clinical symptoms (Kriegstein and Alvarez-Buylla, 2009 ). Therefore, NF1-associated structural brain abnormalities may provide a unique opportunity to define the timing and cellular targets of somatic ''second-hit'' NF1 mutations and, more importantly, the phenotypic consequences of hyperactive RAS/ERK signaling in developing stem cell lineages underlying these brain abnormalities.
Most glial cells in the CC arise from neural progenitor cells that are specified by a basic-helix-loop-helix transcription factor, Olig2, in the subventricular zone (SVZ) of the lateral ventricle during perinatal stages (Marshall et al., 2005; Richardson et al., 2006; Rowitch and Kriegstein, 2010) . Olig2 is both sufficient and necessary for specifying SVZ progenitors to adopt glial fates. Olig2 promotes their differentiation to both oligodendrocytes and astrocytes during neonatal stages, but only to oligodendrocytes in adulthood (Cai et al., 2007; Hack et al., 2005; Marshall et al., 2005; Menn et al., 2006) . Loss of Olig2 leads to a nearly complete absence of glial cells including both oligodendrocytes and astrocytes in the postnatal CC (Cai et al., 2007) . During mouse embryonic development, the SVZ initially is comprised of neuron-restricted progenitors, also known as transit-amplifying progenitors or intermediate progenitor cells (TAP/IPCs), which express Tbr2 and give rise to excitatory projection neurons in the cerebral cortex from embryonic day 14.5 to 17.5 (E14.5-E17.5) (Molyneaux et al., 2007) . When neurogenesis ceases at E17.5 in the cerebral cortex, gliogenesis ensues and persists into postnatal stages. However, one multipotent neural stem cell population with neurogenic activity in the SVZ persists into adulthood, and this region forms the largest germinal zone in the adult brain (Ihrie and Alvarez-Buylla, 2011; Kriegstein and Alvarez-Buylla, 2009 ). The SVZ stem cell lineage is organized in a hierarchy: type B cells (SVZ-B) are multipotent stem cells expressing glial fibrillary acidic protein (GFAP), which give rise to type C cells (SVZ-C) that are multipotent TAP/IPCs. The SVZ-C TAP/IPCs subsequently differentiate into two lineage-restricted progenitors: (1) neuron-restricted type A neuroblasts (SVZ-A) that migrate along rostral migratory stream (RMS) and differentiate into inhibitory neurons in the olfactory bulb (OB), and (2) glia-restricted progenitors that migrate and differentiate into glial cells populating the overlying CC and surrounding brain parenchyma (Ihrie and Alvarez-Buylla, 2011; Kriegstein and Alvarez-Buylla, 2009 ). The cellular output of neonatal and adult SVZ stem and progenitor cells is dramatically different. Although neonatal SVZ cells simultaneously produce a large number of neurons and glial cells in the OB and CC, respectively, adult SVZ cells predominately generate neurons in the OB (>90%) (Hack et al., 2005; Marshall et al., 2005; Menn et al., 2006) . The mechanism(s) by which postnatal SVZ stem and progenitor cells suppress Olig2 expression and maintain high levels of neurogenesis in an otherwise gliogenic environment of the postnatal brain is not well understood.
In this study we developed GEM models that allow spatially and temporarily controlled inactivation of Nf1, and demonstrate the critical role(s) of the Nf1-regulated Erk pathway in embryonic, neonatal, and adult SVZ stem and progenitor cell functions. Furthermore, we define a therapeutic window that may allow treatment of NF1-associated structural brain defects.
RESULTS

Biallelic Inactivation of Nf1
Leads to an Enlarged CC To determine whether biallelic inactivation of Nf1 leads to structural brain defects observed in a subpopulation of NF1 patients, we targeted an Nf1 conditional mutation into radial glia by using a Cre transgenic strain under the control of the human GFAP promoter (hGFAP-cre) (Zhu et al., 2001; Zhuo et al., 2001) . During embryonic development, radial glia are the primary neural stem cell populations, which give rise to neurons, glia, and adult neural stem cells in the SVZ (Kriegstein and Alvarez-Buylla, 2009 ). The onset of hGFAP-cre expression occurs in $95% of E12/E13 radial glia in the forebrain, thus inactivating Nf1 in both embryonic and adult neural stem cells as well as their differentiated progeny (Malatesta et al., 2003) . Nf1 conditional knockout (CKO) mice with the genotypes of hGFAP-cre+; Nf1 ) because both genotypes showed similar phenotypes analyzed in this study. Germline (Nf1 +/À ) or conditional (hGFAP-cre+;Nf1 flox/+ ) heterozygous mice exhibited no overt structural or cellular defects in the brain, indicating that monoallelic Nf1 inactivation is not sufficient to induce the structural brain defects observed in human NF1 patients. In contrast, Nf1 conditional biallelic inactivation caused a 10%-15% increase in the size of cerebral cortical surface area, a manifestation often observed in human NF1 patients ( Figures 1A and 1B) . We next measured and compared the size of the CC at three different sagittal positions along the midline to lateral hemisphere of control and Nf1 hGFAP CKO brains at 2 months of age (Figures 1C and 1C 0 ) . At all three positions that are directly associated with the SVZ of the lateral ventricle (P 1 -P 3 ), Nf1 inactivation caused a significant increase in the thickness of the CC (Figures 1D and 1E ; see Figures S1A-S1C available online). Of note the CC from the midline section, which is not directly associated with the SVZ, showed no increase in thickness ( Figures 1E and S1D ). These observations demonstrate that biallelic, but not heterozygous, inactivation of Nf1 leads to an enlarged CC specifically associated with the SVZ.
To determine the mechanism underlying the enlarged CC, we first examined whether there was an increase in the number of neurons in the cerebral cortex that project their axons to the CC (Molyneaux et al., 2007; Richards et al., 2004 (J an K) Two sets of EM images covering the entire thickness of the CC at two parallel positions (column 1 and column 2) and at comparable histological planes were analyzed. The total number of axons (J) and cell bodies (K) in each column from three controls and three mutants was quantified.
(L) Total cell density in the CC was quantified and compared at P 1 , P 2 , P 3 , and M positions based on H&E-stained sections.
(M-O) Control and mutant CCs were stained for GFAP/Olig2, and their density was quantified in (N). The number of cells expressing both GFAP and Olig2 (arrows, M) was significantly increased in mutant CC (O). Dashed lines delineate the border of the CC. All the quantification data are presented as mean ± SEM. LV and *, lateral ventricle. Scale bars, 50 mm except for (H) and (I) at 2 mm. See also Figure S1 .
whether there was an increase in the number of axons in the Nf1 hGFAP CKO CC. From the coronal sections, we confirmed that the enlargement of the CC occurred specifically in the areas directly associated with the SVZ, but not in the midline ( Figures  1F, S1F , and S1F 0 ). Compared to controls, neurofilament 200 (NF200, an axonal marker) staining revealed a more diffused and reduced expression pattern in the Nf1 hGFAP CKO CC (Figure 1F) . At the ultrastructural level, only a marginal, but not statistically significant, increase in the number of axons was observed in the Nf1 hGFAP CKO CC compared to that of controls ( Figures   1H-1J , S1G, and S1H). In contrast, the number of cell bodies was significantly increased on the same sections analyzed by electron microscopy (EM) ( Figure 1K ). Consistently, a robust increase in both the absolute number and density of cells in the SVZ-associated CC of Nf1 hGFAP CKO brains was observed on thicker sections compared to controls ( Figures 1D, 1L , and S1A-S1C). The increased number in GFAP + and Olig2 + glial lineage cells appeared to be the major contributing factor for the increased cellular density ( Figures 1M-1O ). Together, these results suggest that an increase in the number of glial cells, but not the number of axons or cortical neurons, is mainly responsible for the enlarged SVZ-associated CC in Nf1 hGFAP CKO brains. In support of this conclusion, no CC alteration was observed in neuron-specific Nf1 CKO mice driven by Synapsin I-cre (Figure S1F 00 ) (Zhu et al., 2001) . It is worth noting that despite a relatively normal appearance of myelination (Figure 1G) , varying degrees of tissue degeneration were observed in the CC of Nf1 hGFAP CKO brains ( Figure 1I ).
Nf1-Deficient Adult Brain Exhibits an Enlarged SVZ with Increased Glial Differentiation
Despite a disproportionately enlarged SVZ-associated CC, one discernible structural difference between control and Nf1 hGFAP CKO forebrains was the significantly reduced size of the OB, the destination of SVZ-derived neurons (Figures 1A and 1A 0 ). The contrasting size alterations observed in the two brain structures related to SVZ-derived gliogenesis and neurogenesis raise the possibility that these phenotypes could result from functional impairments of Nf1-deficient SVZ stem and progenitor cells. We therefore analyzed the SVZ from these mice at the same three positions used for the CC studies. At each of these three positions, Nf1 hGFAP CKO SVZ exhibited a 2-to 3-fold size increase compared to controls (Figures 2Aa-2Ab 00 , 2B, and S2A-S2C). To investigate the relative contribution of SVZ cells to its increased size, we determined the number of individual SVZ cell populations by using lineage markers. Compared to controls, the percentage of SVZ cells expressing glial lineage markers including GFAP, Olig2, and NG2 was markedly increased with a concomitant reduction in Doublecortin (Dcx)-expressing neuroblasts in the CKO SVZ/CC system could result from an increase in proliferation or a reduction in apoptosis of SVZ stem and/or progenitor cells, as expected from loss of Nf1 tumor suppressor function. To investigate this possibility, we performed an in vivo bromodeoxyuridine (BrdU)-labeling assay and in vitro neurosphere assays ( Figure S3 ). These studies demonstrate that alterations in proliferation or apoptosis in adult Nf1 Figures 2D-2F ). These results are most consistent with a model wherein Nf1 inactivation promotes ectopic expression of Olig2 specifically in SVZ-C TAP/IPCs that normally undergo neuronal differentiation, leading to an increased output of glial cells at the expense of neuronal differentiation. This hypothesis is supported by the observation that Nf1 inactivation leads to an enlarged CC with a concomitant reduction in OB size.
To further test this hypothesis, we performed a long-term BrdU pulse-chase experiment on 2-month-old control and Nf1 hGFAP CKO mice. Thirty days after BrdU pulses, we analyzed the number and identity of newly generated SVZ- Figures 3E-3G ). Consistently, a nearly 3-fold increase in Olig2-and NG2-expressing cells was observed in the Nf1 hGFAP CKO RMS, some of which expressed myelin basic protein (MBP) ( Figures S4A-S4C ). The abnormal myelination in the mutant RMS may contribute to the progressive disruption of neuronal migratory chain over time ( Figure S4D ). Consistently, Pax6 + / BrdU + -migrating neuroblasts were accumulated and significantly increased in the Nf1 hGFAP CKO RMS compared to controls ( Figures 3E and 3F) . In contrast to a marked increase in gliogenesis in the CC and RMS, the number of BrdU + cells in the OB of Nf1 hGFAP CKO mice was greatly reduced compared to controls ( Figure 3A) Figure S5 ) (Burns et al., 2007) . To target adult SVZ cells, we established a 5 day TM induction protocol from postnatal day 26 (P26) to P30 ( Figure 4A ). TM-induced Nestin-cre ER -mediated recombination specifically targets neural stem and progenitor cells in the SVZ as well as neuroblasts in the RMS, but not cells in the CC or OB of the adult brain ( Figure 4B ). This genetic approach allowed us to perform long-term lineage-tracing analysis for SVZ-derived glial cells in the CC and neurons in the OB because no cells in these two structures were directly targeted by this Nestin-cre ER transgene ( Figure 4O ). We injected TM into control and Nf1
NcreER CKO mice from P26 to P30, and analyzed the distribution and identity of Nestin-cre ER -targeted SVZ/RMS-derived cells 1 month later. At P60, the number of control and Nf1-deficient SVZ cells, marked by b-gal expression, was not significantly different between All the quantification data are presented as mean ± SEM. *, lateral ventricle. Scale bars, 50 mm. See also Figure S4 .
TM-treated control and Nf1
NcreER CKO mice ( Figures 4C and 4D) All the quantification data are presented as mean ± SEM. LV, lateral ventricle. Scale bars, 50 mm. See also Figure S5 .
Alvarez-Buylla, 2011), the b-gal + neuroblasts observed in the RMS 30 days after TM induction would be exclusively derived from multipotent neural stem and progenitor cells in the SVZ ( Figure 4K ). In contrast a considerable number of b-gal + neurons in the OB were derived from Nestin-cre ER -targeted neuroblasts in the RMS. Thus, a 2-fold decrease in the number of SVZderived neuroblasts in the mutant RMS opposed to a marginal reduction in SVZ-derived neurogenesis in the mutant OB could reflect the fact that Nf1 has a dispensable role in neuroblast migration and differentiation ( Figures 4M-4O ). Collectively, these observations demonstrate that acute inactivation of Nf1 confers no proliferative advantage to adult SVZ cells but, instead, alters glial/neuronal fate specification by promoting Olig2 expression in adult SVZ progenitor cells in a cell-autonomous manner.
Nf1 Suppresses Olig2 Expression in Neonatal SVZ Progenitor Cells
Despite an ongoing requirement for Nf1 function in regulating fate specification of adult SVZ progenitor cells, acute inactivation of Nf1 in adult SVZ cells did not produce any of the structural defects (e.g., enlarged CC or SVZ) observed in Nf1 hGFAP CKO brains. We therefore sought to investigate the timing and mechanism(s), when and by which Nf1 inactivation leads to impaired fate specification of SVZ cells and enlarged CC during development. We measured the size and cell number of the anterior SVZ (SVZa) and posterior SVZ (SVZp), and no significant difference was identified between control and Nf1 hGFAP CKO forebrains at birth (Figures 5Aa, 5Aa 0 , S6A, and S6D). The overall rate of proliferation or apoptosis in the SVZ was not significantly altered ( Figures S6B and S6C) 
Nf1-Related Structural Brain Defects Are Established during Neonatal Development
We observed no significant difference in the size of control and Nf1 hGFAP CKO brains including OB at P0.5 and P8 ( Figures 6A-6C ). However, by P18 the size of the mutant OB was significantly reduced to a similar degree to that observed in the adult ( Figures  6D and S8E) . Notably, neuronal clusters, which could be readily identified in the control OB, were largely absent in mutants (Figure 6E ). These observations suggest that the glial/neuronal fatespecification defect caused by Nf1 inactivation is largely established during postnatal stages from P8 to P18. Figure 6K ) (Cai et al., 2007; Marshall et al., 2005) . It is worth noting that the size and cell number of Nf1 hGFAP CKO SVZ were already significantly increased at P8, and this was accompanied by an increase in proliferation of GFAP + stem cells (Figures 6L-6N ). Because Nf1 inactivation confers no growth advantage to adult SVZ cells, this observation suggests that Nf1 is only transiently required for regulating SVZ stem cell proliferation in the early postnatal brain. However, the overall proliferation rate in Nf1 hGFAP CKO SVZ was not significantly altered, which was at least partially attributed to a slightly reduced proliferation of Olig2 + cells ( Figures 6O-6Q ) (Lee et al., 2010) . Most of the differentiated Olig2 + cells, which were negative for Ki67 expression, accumulated in the anterior-dorsal parts of the SVZ ( Figure 6P, arrowheads) , an area where an excessive number of differentiated astrocytes were observed in the adult Nf1 hGFAP CKO SVZ (Figure 2A ). Taken together, these results demonstrate that ectopic expression of Olig2 in Ascl1 + progenitors caused by Nf1 inactivation manifests during neonatal stages ( Figure 6R ), leading to increased gliogenesis in the CC at the expense of neurogenesis in the OB. Consequently, Nf1-related structural brain defects including enlarged CC and reduced OB are both established during early postnatal stages.
Neonatal Erk Pathway Inhibition Rescues Structural Brain Defects Caused by Nf1 Inactivation
To investigate the molecular mechanism underlying ectopic Olig2 expression in Nf1-deficient SVZ progenitors, we performed a series of in vitro and in vivo experiments. We showed that activation of Erk signaling pathway, but not phosphatidylinositol 3-kinase (PI3K)/Akt or mammalian target of rapamycin complex 1 (mTORC1), was associated with ectopic Olig2 expression in Ascl1 + TAP/IPCs (Figures S8A-S8C ; data not shown). In paraffin-embedded brain sections, robust p-Erk staining was only identified in a small number of SVZ cells in control neonatal brains and was reduced to a minimal level in the control adult SVZ ( Figures S8A-S8B  00 ) , which is correlated with the diminished gliogenic output in the adult SVZ. In contrast, p-Erk + cells
were readily detected and greatly increased in both neonatal and adult SVZ To test this model, we treated mice from P0.5 to P18 with a potent MEK/ERK pathway inhibitor (MEKi), PD0325901 (Sebolt- Leopold and Herrera, 2004) . Despite being relatively normal at birth, Nf1 hGFAP CKO mice became hunched, scruffy, and exhibited growth retardation within 1 week. Consequently, Nf1 hGFAP CKO mice can be readily identified from control littermates from P8 on, and weighed only half as much as control littermates by P18 ( Figures 7A and 7B ). Strikingly, this P0.5-P18 treatment protocol completely rescued these phenotypes. For example, the appearance of the MEKi-treated Nf1 hGFAP CKO mice was indistinguishable from control littermates at P18 ( Figures 7A and 7B ). The level of Erk activation in MEKi-treated Nf1 hGFAP CKO SVZ at P18 was reduced to the level of control SVZ, and more importantly, the number of Olig2 + cells in the mutant SVZ was rescued to the level of vehicle-treated controls ( Figures 7C-7C  00 ). For the Ascl1 + progenitors, the percentage of Olig2 + cells in MEKi-treated Nf1 hGFAP CKO SVZ was also reduced to control levels ( Figure 7C  00 ). In the CC, the density of Olig2 + cells and GFAP + cells in MEKi-treated Nf1 hGFAP CKO brains, albeit not completely rescued, was reduced to nearly the levels of vehicle-treated controls ( Figures 7D-7D 00 ). Most importantly, the enlarged CC phenotype was completely rescued in the MEKi-treated Nf1 hGFAP CKO brains ( Figures 7D and 7D 0 ). Conversely, neuronal density and the size of the OB were significantly increased in mutants after MEKi treatment, particularly evidenced by the reappearance of neuronal clusters that were only observed in the control OB ( Figures 7E, E 0 , and S8E-S8E 00 ). These MEKi treatment experiments demonstrate a potential therapeutic window for preventing and treating NF1-associated structural brain defects.
DISCUSSION
Given the well-documented role of ERK activity in synaptic transmission and memory formation, pharmacological intervention of RAS/ERK signaling could provide an attractive therapeutic strategy to ameliorate the substantial neurocognitive burden associated with the NCFC syndromes (Davis and Laroche, 2006; Samuels et al., 2009) . However, it is unclear to what degree development-related structural brain abnormalities contribute to the cognitive deficits in NCFC syndrome patients. Recent studies have revealed that the structural brain abnormalities, particularly an enlarged CC, are identified in a subpopulation of NF1 patients with severe learning disabilities (Moore et al., 2000; Payne et al., 2010; Pride et al., 2010) . These observations provide strong support for the hypothesis that these structural brain abnormalities could be responsible for the severe forms of cognitive impairment observed in a subset of NCFC patients. Thus, our study elucidates the timing, and cellular and molecular mechanism(s), when and by which hyperactive RAS/ERK signaling leads to the development-related structural brain defects caused by biallelic Nf1 inactivation. More importantly, we demonstrate the neonatal stage(s) as a critical therapeutic window for treating these brain abnormalities.
Biallelic Inactivation as an NF1-Related Nontumor Disease Mechanism
The mechanism underlying the extremely high level of variability in disease manifestation among NF1 patients, even for those with the same germline heterozygous mutations, is poorly understood (Riccardi, 1992) . Our study demonstrates that biallelic, but not heterozygous, inactivation of Nf1 leads to structural brain defects including enlarged CC. Moreover, our study shows that biallelic inactivation of Nf1 in developing, but not adult, neural stem cells results in an enlarged CC. The results are consistent with the observations that (1) most glial cells in the CC are generated by SVZ stem cells during perinatal stages, and (2) only a minor population of the progeny derived from adult SVZ stem cells contributes to glial cells in the CC (Marshall et al., 2005; Richardson et al., 2006; Rowitch and Kriegstein, 2010) . Therefore, these observations suggest that the timing and cellular target(s) of somatic ''second-hit'' events could profoundly impact on the severity of disease manifestations, thus providing a potential mechanism underlying high levels of disease variability observed among NF1 patients. It has been well established that benign and malignant tumors arising in NF1 patients result from biallelic inactivation of NF1 (Cichowski and Jacks, 2001) . NF1 À/À tumor cells exhibit growth advantage, leading to clonal expansion and thus clinically identifiable diseases in NF1 patients. Similarly, because of the substantial self-renewal capacities possessed by developing stem and progenitor cell populations, a relatively small number of somatic ''second-hit'' events in these cells could produce a greater number of NF1 À/À progeny, leading to more severe phenotypic consequences than those with the ''second-hit'' events in differentiated cells. It would be of particular interest to determine whether somatic ''second-hit'' NF1 mutations indeed occur in cells within the enlarged CC from human specimens, as previously demonstrated in other NF1-related nontumor lesions including skin hyperpigmentation and bone abnormalities (De Schepper et al., 2008; Stevenson et al., 2006) . Alternatively, a subset of NF1 +/À cells could phenotypically behave like NF1 À/À cells when they have aberrantly high activity of a recently identified ubiquitin-mediated NF1 degradation machinery (Tan et al., 2011) .
The Role of Nf1 in SVZ Stem and Progenitor Cells in the Brain During embryonic development, neurogenesis and gliogenesis are temporally regulated and occur sequentially in the developing VZ and SVZ (Kriegstein and Alvarez-Buylla, 2009; Molyneaux et al., 2007) . Recent studies using the same hGFAP-cre driver show that Erk1 and Erk2 double-knockout mice exhibit a significantly thinner VZ and SVZ and a reduction in the size of the CC; likewise, Erk2 loss results in reduced proliferation of SVZ TAP/IPCs during embryonic cortical development (Samuels et al., 2008; Satoh et al., 2011) . These mouse genetic studies support the notion that ERK/Erk signaling pathway has an essential role in both human and mouse embryonic cortical development. However, our study shows that Nf1 has a dispensable role in embryonic cortical development. Specifically, the number of deep-and upper-layer neurons as well as laminar organization of the cerebral cortex appear to be relatively normal in Nf1 hGFAP CKO brains. In the neonatal and adult SVZ, neurogenesis and gliogenesis occur simultaneously (Kriegstein and Alvarez-Buylla, 2009 ). Our study indicates that the percentage of Ascl1 + TAP/IPCs expressing Olig2 is highly correlated with the glial output of neonatal and adult SVZ stem cell niches, $20% and $9%, respectively. This observation is consistent with previous studies showing that the regulation of Olig2 expression in the Ascl1 + TAP/IPC compartment appears to be a critical mechanism controlling the balance between gliogenesis and neurogenesis in the postnatal SVZ stem cell niche (Cai et al., 2007; Hack et al., 2005; Marshall et al., 2005; Menn et al., 2006) . Although Olig2 expression is activated by Sonic hedgehog (Shh) signaling in developing ventral spinal cord and forebrain, the signaling pathway(s) regulating Olig2 is relatively less understood in the dorsal forebrain (Lagace et al., 2007; Lu et al., 2000; Zhou et al., 2000) . In cultured neural precursor cells, fibroblast growth factor 2 (FGF2) promotes Olig2 expression in an Erk-dependent but Shh-independent manner (Bilican et al., 2008; Chandran et al., 2003; Kessaris et al., 2004) . In light of these in vitro studies, our study provides compelling in vivo evidence supporting that Nf1-regulated Erk signaling plays a critical role in regulating Olig2 in both neonatal and adult SVZ cells. Based on these observations, we propose that FGF-mediated Ras/Erk signaling pathway induces Olig2 expression, triggering the transition from neurogenesis to gliogenesis at the end of cortical development. The critical role of Nf1 is to inhibit Ras/ Erk activity and, in turn, suppress Olig2 expression in a subset of Ascl1 + TAP/IPCs, thereby ensuring persistent neurogenesis in an otherwise gliogenic environment of the perinatal and adult brain ( Figure 7F ). This model is supported by the observations that hyperactive Erk signaling and ectopic Olig2 expression in Nf1 hGFAP CKO brains are almost exclusively observed in SVZ-C Ascl1 + TAP/IPCs, but not in any other SVZ lineage cells. Thus, our study demonstrates that the regulation of Erk signaling pathway by Nf1 mainly occurs at the stages of SVZ TAP/IPC cells. It is worth noting that Nf1 has functions that are critical for glia and neurons in the other regions of the brain (Hegedus et al., 2007; Lee et al., 2010; Zhu et al., 2005) . Together, these studies suggest that individual ERK pathway components (e.g., NF1) may be rate limiting only in specific cell types and/ or during specific developmental stages, and this could contribute to phenotypic heterogeneity among NCFC syndromes.
Clinical Implication-A Therapeutic Window of Opportunity The most striking finding of this study is the robust therapeutic response when an 18 day MEKi treatment protocol was delivered to neonatal Nf1 hGFAP CKO mice, which suffer from structural brain defects (e.g., enlarged CC and reduced OB), weight loss, and deteriorating health. Remarkably, this MEKi treatment protocol not only rescues SVZ-associated glial versus neuronal fate-specification defects and the size abnormalities observed in the CC and OB but also dramatically improves the overall health of Nf1 hGFAP CKO mice ( Figure 7A ). These observations suggest that Nf1-related brain pathologies are mainly caused by hyperactivation of the Erk/MAPK signaling pathway, but not other Ras-mediated signaling pathways (e.g., PI3K/Akt). Furthermore, clinical studies indicate that optic nerve gliomas only develop in younger children (<6 years) with NF1 and that nearly half of plexiform neurofibromas are identified in children younger than 5 years with NF1 (Listernick et al., 1999; Waggoner et al., 2000) . Taken together, we propose that this transient MEKi treatment protocol during early postnatal stages might represent an exciting opportunity to prevent and treat multiple NF1-associated tumor and nontumor manifestations including structural brain defects, which are associated with severe learning disabilities and are previously thought to be ''irreversible'' due to their hypothetical origin during embryonic development.
(D) The size of P18 control and Nf1 hGFAP CKO OB was quantified. All the quantification data are presented as mean ± SEM. *, lateral ventricle. Scale bars, 1 mm (A and B) and 50 mm (E-P). See also Figure S7 . mice were maintained on the mixed C57Bl6 and 129Svj backgrounds. Ageand littermate-matched control and mutant mice were used for analysis to minimize the impact of modifier genes. All mice in this study were cared for according to the guidelines that were approved by the Animal Care and Use Committees of the University of Michigan at Ann Arbor.
MEK Inhibitor Treatment
MEK inhibitor (PD0325901; Sigma-Aldrich) was dissolved in DMSO at a concentration of 25 mg/ml and resuspended in vehicle (0.5% hydroxypropyl methyl-cellulose with 0.2% Tween 80; Sigma-Aldrich) at a concentration of 1 mg/ml. The solution was administered by oral gavage at the dosage of 5 mg/kg (body weight) daily to lactating females for the treatment of P0.5-P18 mice. MEK inhibitor-treated mice were collected and compared to littermate control and Nf1 hGFAP CKO mice treated with vehicle. All the quantification data are presented as mean ± SEM. Scale bars, 50 mm. See also Figure S8 .
